The U.S. exosomes market was valued at US$ 75.30 million in 2023 and is projected to reach US$ 1,428.79 million by 2033, registering a CAGR of 34.22% from 2024 to 2033. The increasing number of cases of chronic conditions is driving the growth of the U.S. exosomes market.
Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5158
The U.S. exosomes market is expanding because of the increasing use of exosomes in diagnosing and treating various diseases and health conditions. Exosomes belong to a group of extracellular vesicles that come from the endosomal system and usually measure between 30 to 150 nanometers in size, making them the smallest kind of extracellular vesicle. These vesicles are surrounded by a lipid bilayer and are released into the surrounding space, carrying a mix of complex materials from the cell they originated from, such as proteins, lipids, mRNA, miRNA, and DNA. They serve the function of transporting and exchanging different substances between cells and are utilized as non-invasive indicators for various diseases.
| Company Name | Celularity Inc. |
| Headquarters | New Jersey, U.S. |
| Pipeline | The firm is working on creating placental exosomes (pExo) as possible therapies that can transport growth-promoting factors, aiding in the formation of neural cells, blood vessels, and muscle tissue. pExo shows specific markers for exosomes, such as CD9, CD63, and CD81, and holds more than a thousand unique proteins and microRNAs that play roles in various biological processes. pExo includes various types of cytokines and chemokines and helps grow primary human cells from various organs and tissues. The pExo pipeline is currently being assessed for potential uses in treating regenerative and age-related conditions at the pre-clinical level. |
| Company Name | Aethlon Medical |
| Headquarters | California, U.S. |
| Pipeline | In May 2024, the company announced the positive results of the phase I trial of Hemopurifier®. It will now move to the next stage. Designed to quickly reduce circulating viruses and exosomes that promote cancer, the Aethlon Hemopurifier® is a pioneering technology. The Hemopurifier® is a “Breakthrough Device” according to the FDA, meaning that it can be used to treat patients with life-threatening viruses that are not treated by approved therapies, as well as patients with advanced or metastatic cancer who are either intolerant of or unresponsive to standard-of-care therapy. |
Exosomes are vesicles released from cells that are crucial for communication between cells and are found in many bodily fluids such as blood, saliva, urine, and cerebrospinal fluid, among others. Exosomes are evidently occurring compounds that may withstand digestive enzymes because of the innate residences of exosomes, including their capability tissue of mobile selectivity. The capability to go blood-mind barriers causes fewer systemic consequences and occasional toxicity. These vesicles are particularly well-suited for cancer detection due to their distinct features. They are also valuable in predicting and identifying a range of illnesses, including cancer, heart and age-related diseases, arthritis, brain disorders, and diabetes.
Additionally, exosomes are utilized in medical research and early-stage clinical studies. In recent years, cures using extracellular vesicles have garnered substantial attention among industry stakeholders to remedy numerous target warning signs, generally owing to their numerous applications, including goal specificity, more advantageous tissue regeneration, and reduced irritation and chronic pain.
By Product Type
By Workflow Type
By Application Type
By End-use Type
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/us-exosomes-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5158
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Contract Development and Manufacturing Organizations (CDMOs) play a crucial role in the pharmaceutical and biotechnology industries by providing essential services… Read More
The global medical rehabilitation services market has been experiencing significant expansion, driven by various factors such as an aging population,… Read More
The global antibody drug market is experiencing rapid growth, with a notable surge in monoclonal antibody (mAb) demand. The market… Read More
Stroke rehabilitation plays a crucial role in helping individuals regain independence and improve their quality of life following a stroke.… Read More
Healthcare is a multifaceted domain, catering to various needs and conditions. The concept of ambulatory wellness services, which focus on… Read More
Artificial Intelligence (AI) and Machine Learning (ML) have rapidly evolved from emerging technologies to integral components in a variety of… Read More